CTNI-53. A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS
CTNI-53. 一项全球性、随机、双盲、3期研究,比较沃拉西地尼与安慰剂治疗携带IDH1/2突变的成人型弥漫性胶质瘤患者的疗效(INDIGO):最新疗效结果
期刊:Histopathology
影响因子:4.1
doi:10.1111/his.15364
Dodington, David W; Serra, Stefano; Bracey, Tim; Chetty, Runjan; Nowak, Klaudia M; Mellinghoff, Ingo K; van den Bent, Martin J; Touat, Mehdi; Blumenthal, Deborah T; Peters, Katherine B; Ellingson, Benjamin M; Clarke, Jennifer L; Mendez, Joe; Yust-Katz, Shlomit; Mason, Warren P; Ducray, Francois; Umemura, Yoshie; Nabors, Burt; Hottinger, Andreas F; Arakawa, Yoshiki; Sepulveda, Juan M; Wick, Wolfgang; Soffietti, Riccardo; Perry, James R; Giglio, Pierre; de la Fuente, Macarena; Maher, Elizabeth A; Tron, Adriana E; Zhao, Dan; Pandya, Shuchi S; Steelman, Lori; Hassan, Islam; Wen, Patrick Y; Cloughesy, Timothy F